JP2018518485A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518485A5
JP2018518485A5 JP2017563292A JP2017563292A JP2018518485A5 JP 2018518485 A5 JP2018518485 A5 JP 2018518485A5 JP 2017563292 A JP2017563292 A JP 2017563292A JP 2017563292 A JP2017563292 A JP 2017563292A JP 2018518485 A5 JP2018518485 A5 JP 2018518485A5
Authority
JP
Japan
Prior art keywords
polypeptide
peg
pharmaceutical composition
lipid
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017563292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518485A (ja
JP6811190B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/063206 external-priority patent/WO2016198544A1/en
Publication of JP2018518485A publication Critical patent/JP2018518485A/ja
Publication of JP2018518485A5 publication Critical patent/JP2018518485A5/ja
Application granted granted Critical
Publication of JP6811190B2 publication Critical patent/JP6811190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017563292A 2015-06-10 2016-06-09 プロテアーゼ耐性脂質付加glp−1類似体 Active JP6811190B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562173631P 2015-06-10 2015-06-10
US62/173,631 2015-06-10
US201662343390P 2016-05-31 2016-05-31
US62/343,390 2016-05-31
PCT/EP2016/063206 WO2016198544A1 (en) 2015-06-10 2016-06-09 Protease-resistant lipidated glp-1 analogs

Publications (3)

Publication Number Publication Date
JP2018518485A JP2018518485A (ja) 2018-07-12
JP2018518485A5 true JP2018518485A5 (cg-RX-API-DMAC7.html) 2019-05-23
JP6811190B2 JP6811190B2 (ja) 2021-01-13

Family

ID=56235790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017563292A Active JP6811190B2 (ja) 2015-06-10 2016-06-09 プロテアーゼ耐性脂質付加glp−1類似体

Country Status (25)

Country Link
US (3) US10414811B2 (cg-RX-API-DMAC7.html)
EP (2) EP3307769B1 (cg-RX-API-DMAC7.html)
JP (1) JP6811190B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180016441A (cg-RX-API-DMAC7.html)
CN (1) CN108271373B (cg-RX-API-DMAC7.html)
AU (2) AU2016277449B2 (cg-RX-API-DMAC7.html)
CA (1) CA2988841C (cg-RX-API-DMAC7.html)
CL (1) CL2017003144A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017012675A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170559A (cg-RX-API-DMAC7.html)
DO (1) DOP2017000287A (cg-RX-API-DMAC7.html)
EA (1) EA036415B1 (cg-RX-API-DMAC7.html)
ES (1) ES2849950T3 (cg-RX-API-DMAC7.html)
IL (1) IL255978B (cg-RX-API-DMAC7.html)
MX (1) MX389407B (cg-RX-API-DMAC7.html)
MY (1) MY185816A (cg-RX-API-DMAC7.html)
NI (1) NI201700156A (cg-RX-API-DMAC7.html)
NZ (1) NZ738909A (cg-RX-API-DMAC7.html)
PE (1) PE20180659A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017502259A1 (cg-RX-API-DMAC7.html)
SG (1) SG10201911837SA (cg-RX-API-DMAC7.html)
SV (1) SV2017005585A (cg-RX-API-DMAC7.html)
TN (1) TN2017000519A1 (cg-RX-API-DMAC7.html)
TW (1) TWI726889B (cg-RX-API-DMAC7.html)
WO (1) WO2016198544A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018072968A2 (pt) * 2016-06-09 2019-02-19 Medimmune Limited peptídeos monolipidados resistentes às proteases
JP2021501172A (ja) * 2017-10-31 2021-01-14 メドイミューン・リミテッドMedImmune Limited Glp−1ペプチド類似体の経口送達
HUE067499T2 (hu) 2018-04-05 2024-10-28 Sun Pharmaceutical Ind Ltd Új GLP-1 analógok
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的glp—1及升糖素雙重激動肽

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JP2006501820A (ja) 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾glp−1受容体アゴニストおよびそれらの薬理学的使用法
CN101010339B (zh) * 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
BRPI0615573A2 (pt) * 2005-09-08 2011-05-24 Tufts College análogos de glp-1 estabilizados
DE602006009631D1 (de) * 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
EP2057189B1 (en) 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
EP2231701B1 (en) 2007-12-11 2012-04-18 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
EP2364326B1 (en) * 2008-12-05 2018-07-04 Glaxo Group Limited Methods for selecting protease resistant polypeptides
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
US20120264685A1 (en) 2009-10-22 2012-10-18 Rajesh Bahekar Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
CN103079587B (zh) 2010-05-13 2016-05-11 印第安纳大学研究及科技有限公司 呈现核激素受体活性的胰高血糖素超家族肽
US20130143800A1 (en) 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
WO2014049610A2 (en) * 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
US20130303436A1 (en) 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
EP3238734A1 (en) * 2013-03-14 2017-11-01 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
JP2017502003A (ja) 2013-12-13 2017-01-19 メディミューン リミテッド プロテアーゼ耐性ペプチド

Similar Documents

Publication Publication Date Title
JP2018518485A5 (cg-RX-API-DMAC7.html)
JP6229038B2 (ja) 修飾された血管作動性腸管ペプチド
JP2011526303A5 (cg-RX-API-DMAC7.html)
CN103003300B (zh) Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
JP2025093970A (ja) インクレチン類似体およびその使用
JP2007001987A5 (cg-RX-API-DMAC7.html)
AU2017371516A1 (en) Acylated GLP-1/GLP-2 dual agonists
JP2018135346A5 (cg-RX-API-DMAC7.html)
RU2007134155A (ru) Glp-1 соединения с увеличенным временем полужизни
JP2018515088A5 (cg-RX-API-DMAC7.html)
TWI353250B (en) Glp-1 pharmaceutical compositions
CN105263957A (zh) 治疗肽
CN101213209A (zh) 新颖化合物及它们对进食行为的影响
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
BRPI1008061B1 (pt) Polipeptídeos recombinantes estendidos (xten), proteína de fusão isolada compreendendo os mesmos e método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
JP2013515057A5 (cg-RX-API-DMAC7.html)
AU2017373901A1 (en) GLP-1/GLP-2 dual agonists
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP6811190B2 (ja) プロテアーゼ耐性脂質付加glp−1類似体
JP2010174016A (ja) Glp−1類似体
CN106255701A (zh) 可从前胰高血糖素原衍生出的肽激素类似物
JP2007524579A (ja) Glp−1の類似体
CN105801705A (zh) 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途
JP2025178483A (ja) ポリペプチドを含む医薬組成物
AU2017277594A1 (en) Protease-resistant mono-lipidated peptides